All In Biotech

Free tool

FAERS Monitor: Oxervate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761094 or its brand name (Oxervate, Cenegermin-Bkbj). Reports on generic versions are filed under their own applications.

Reports

13,495

Serious

1,498

11% of reports

Hospitalization

799

Death reported

220

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain6,508
  • eye irritation2,111
  • product dose omission issue1,456
  • ocular hyperaemia1,360
  • photophobia1,209
  • vision blurred1,053
  • eye swelling959
  • wrong technique in product usage process949
  • ocular discomfort908
  • lacrimation increased822
  • eyelid pain797
  • headache773
  • off label use773
  • product administration error660
  • therapy interrupted609

Reports by year received

View as table
YearReports
20171
2019488
2020661
20211,094
20221,926
20232,337
20242,274
20253,179
20261,535

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,664 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eyelid painSignal7971004.6920.5485,381
eye painSignal6,508203.1199.11,160,704
ocular discomfortSignal908137.0128.3112,647
photophobiaSignal1,209107.0101.2118,777
eye irritationSignal2,11159.357.0116,823
product administration errorSignal66052.648.732,287
ocular hyperaemiaSignal1,36046.043.758,178
lacrimation increasedSignal82243.640.733,255
eye swellingSignal95941.238.736,682
therapy interruptedSignal60913.412.46,932
vision blurredSignal1,05312.011.410,633
product dose omission issueSignal1,4567.87.48,632
wrong technique in product usage processSignal9497.36.95,206
headache7731.91.8351
off label use7731.41.382

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.